Ozempic · Wegovy · GLP-1 Agonist
The breakthrough GLP-1 agonist for sustainable weight loss
Typical Dose
0.5–2.4 mg per week
Route
Subcutaneous
Frequency
Once weekly
Cycle
Ongoing (chronic use)

You have almost certainly heard of Semaglutide — it is the active ingredient in Ozempic and Wegovy. It works by mimicking a hormone your gut naturally releases after you eat, called GLP-1. That hormone tells your brain you are full and tells your pancreas to manage blood sugar. Semaglutide does the same thing, but lasts much longer in your body. The result is that people feel full sooner, eat less, and lose significant weight. It is one of the most studied and prescribed medications in the world right now. If you are wondering how it compares to newer options, see our Tirzepatide page (dual GIP/GLP-1) and Retatrutide page (triple receptor) for the full GLP-1 family comparison.
Semaglutide activates GLP-1 receptors in three key places. In your brain, it dials down appetite and cravings. In your pancreas, it helps release insulin when blood sugar is high (and stops the hormone that raises blood sugar). In your stomach, it slows down how fast food moves through, which keeps you feeling full longer. All three effects work together to reduce how much you eat and how your body handles the calories you do consume.
Typical Dose
0.5–2.4 mg per week
Dose Range
0.25 mg (starting) to 2.4 mg (maintenance)
Frequency
Once weekly
Route
Subcutaneous injection
Cycle Length
Ongoing (chronic use)
CLINICAL NOTES
Dose is titrated up slowly over 16–20 weeks to minimize GI side effects. Must be prescribed by a physician.
IMPORTANT DISCLAIMER
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol. Individual responses vary and medical supervision is recommended.
GLP-1 agents are typically run solo or with metabolic support peptides. Avoid stacking with other appetite suppressants.
BPC-157 can help mitigate the GI side effects (nausea, gastroparesis) common with semaglutide.
Tesamorelin targets visceral fat specifically while semaglutide drives overall weight loss — a powerful metabolic combination.
AOD-9604's fat-burning mechanism complements semaglutide's appetite suppression for enhanced body composition.
Real experiences from the Peptide Insights community
Real experiences from real people help others make informed decisions. Share what worked, what didn't, and what you wish you'd known before starting.
Free account required. Your review helps the Peptide Insights community.
Be the first to share your experience. Your insight could help someone else decide if Semaglutide is right for them.
Sign In to Be the FirstGet our free 32-page Beginner's Guide — plain-language breakdowns of the top peptides, dosing essentials, and safety basics.
32-page PDF, instant download
Compounds often researched alongside Semaglutide
Next-generation triple hormone agonist with the most powerful weight loss data ever recorded in a clinical trial
Long-acting amylin analog with additive weight loss when combined with semaglutide
FDA-approved GHRH analog for visceral fat reduction
A fragment of HGH specifically targeting fat metabolism